Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

ClinicalTrials.gov ID: NCT04469075

Public ClinicalTrials.gov record NCT04469075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields

Study identification

NCT ID
NCT04469075
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
48 participants

Conditions and interventions

Interventions

  • Clindamycin Phosphate Drug
  • Triamcinolone Acetonide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 8, 2020
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update posted
Aug 7, 2025

2020 – 2026

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Northwestern University Evanston Illinois 60208
Tufts Medical Center Boston Massachusetts 02111
Washington University School of Medicine St Louis Missouri 63110
Hackensack Meridian Health Hackensack New Jersey 07601
Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities) Hauppauge New York 11788
Memorial Sloan Kettering Cancer Center New York New York 10021
Columbia University New York New York 10032
University of Cincinnati Medical Center Cincinnati Ohio 45219

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04469075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 7, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04469075 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →